Clinical Trials Logo

Stage III Rectal Cancer clinical trials

View clinical trials related to Stage III Rectal Cancer.

Filter by:

NCT ID: NCT00019006 Completed - Clinical trials for Recurrent Rectal Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Start date: March 1995
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.

NCT ID: NCT00006094 Completed - Clinical trials for Adenocarcinoma of the Rectum

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

Start date: July 2000
Phase: Phase 1/Phase 2
Study type: Interventional

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may be a more effective treatment for cancer of the rectum. Phase II trial to study the effectiveness of combining oxaliplatin, fluorouracil, and external-beam radiation therapy followed by surgery in treating patients who have locally advanced cancer of the rectum

NCT ID: NCT00005818 Completed - Clinical trials for Recurrent Rectal Cancer

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Start date: March 2000
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy